


STING agonist-9

Cat. No.:	HY-147834
CAS No.:	2653337-73-4
Molecular Formula:	C ₃₉ H ₄₇ N ₁₃ O ₆ S
Molecular Weight:	825.94
Target:	STING
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	STING agonist-9 (Compound 45) is a potent STING agonist with an EC ₅₀ of 1.2 nM and 32.82 μM against h-STING and m-STING, respectively. STING agonist-9 shows antitumor activity ^[1] .
IC₅₀ & Target	EC ₅₀ : 1.2 nM (h-STING), 32.82 μM (m-STING) ^[1]
In Vitro	STING agonist-9 (Compound 45) directly binds to various h-STING isoforms and m-STING ^[1] . STING agonist-9 potently activates both ISG and NF-κB signaling pathways ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	STING agonist-9 (Compound 45) significantly inhibits the tumor growth in allograft 4T1 and CT26 tumor models by systemic administration, and induces tumor regression in CT26 tumor model without inducing weight loss ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Niu J, et al. Discovery of novel Thieno[2,3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration. Eur J Med Chem. 2022 Aug 5;238:114482.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA